Significant intracranial and extracranial responses were reported with the use of cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma (RCC) and brain metastases.
Results showed that in patients with uncontrolled brain metastases at baseline (n = 25) who received cabozantinib, the intracranial response rate was 61% (95% CI, 39%-80%); this comprised a 13% complete response (CR) rate and a 48% partial response (PR) rate. Thirty percent and 9% of patients experienced stable disease (SD) and progressive disease (PD), respectively.
In those who had controlled brain disease at baseline (n = 44), the intracranial response rate was 57% (95% CI, 41%-72%), which included all PRs. The SD and PD rates were 31% and 12%, respectively.
“This is the largest cohort of patients with metastatic renal cell carcinoma with concomitant brain metastases treated by cabozantinib,” lead…